CARDIAC ARRHYTHMIA SUPPRESSION TRIAL

该承包商将成为协作临床的临床中心 试验，心律失常治疗研究(CATS)。的主要目标是 这份合同是为了看看药物治疗频发的脑室是否有效 心肌梗死后患者的过早除极将 减少心源性猝死的发生率；次要目标是 (1)评估治疗对全因死亡率的影响；(2)评估 药物不良反应，(3)检查本病的临床病程 对照组，以及(4)进行选定的亚研究以明确疾病 药效过程和药效机制。为期三年的招聘 在十个月的规划阶段之后，设计了一个周期。后续行动将 在病人招募之后继续两年。

This contractor will be a clinical center for the collaborative clinical trial, Cardiac Arrhythmia Treatment Study (CATS). The primary objective of this contract is to see if effective drug treatment of frequent ventricular premature depolarizations in post-myocardial infarction patients will reduce the incidence of sudden cardiac death; secondary objectives are to (1) assess the impact of treatment on all-cause mortality, (2) evaluate adverse drug effects, (3) examine the clinical course of the disease in the control group, and (4) conduct selected substudies to clarify the disease process and the mechanisms of drug efficacy. A three-year recruitment period is designed, following a ten-month planning phase. Follow-up will continue two years beyond patient recruitment.